Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Thyrocare Technologies Limited

NSE: THYROCAREHealthcare Service Provider

Share price

₹499.70

-0.26% close of 9 Oct 2026

Market cap ₹7,945 CrP/E 44.1

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

73

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹7,945 Cr

P/E ratio

44.1

P/B ratio

13.6

ROCE

35.4%

ROE

28.4%

Dividend yield

1.8%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹649.3552-week low ₹349.55

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 21.1% over the past year, and 10.9% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 34.7% to 32.1% over the last four years.

Whether it grew faster than its sector

It grew 10.9% a year against a sector median of 13.1% — 2.2 percentage points slower.

Room to re-rate, or risk of de-rating

At 44.1× earnings it costs 1.8× the market, which pays 24.1× across 2199 companies we can price. Its own industry sits at 57.7×, across 5 companies. It is against its own five-year median of 48.2×, the 34th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.2 times its growth rate, on earnings growth of 36%.

Profit growthPrice per ₹1 profitPer 1% growth
Thyrocare Technologies Limited — this one36%/yr44.1×₹1.2
Dr. Lal Path Labs Ltd.30%/yr57.7×₹1.9
Vijaya Diagnostic Centre Limited24%/yr76.8×₹3.2
Metropolis Healthcare Limited11%/yr51.9×₹4.7
Nephrocare Health Services Limited103%/yr72.4×—
Krsnaa Diagnostics Limited18%/yr17.6×₹0.98

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 3 of 12 on returns, 10 of 11 on growth, 5 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 35.4% on capital, ahead of 75% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹814 crore of cash from the business, spent ₹176 crore on plant and equipment, and returned ₹560 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 138 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 41 days for its cash to waiting 19 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

10 of 10 checks clear · 100%

How the profit check works

Latest result · Q2 FY26

What the last results showed. Whether management kept its word is in Pro.

Announced 3 Aug 2026 · Standalone · Unaudited

Revenue

₹202 Cr

Revenue vs last year

+14.3%

Revenue vs last quarter

+4.8%

Net profit

₹43 Cr

Profit vs last year

+65.5%

Profit vs last quarter

+13.2%

Net margin

21.3%

EPS

₹8.12

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹7,945 Cr
Prev close
₹499.70
52w High
₹662
52w Low
₹343
Enterprise value
₹7,777 Cr
Beta
0.4
Price CAGR 1y
25.0%
Price CAGR 3y
40.0%
Price CAGR 5y
6.0%
Price CAGR 10y
9.0%

Ratios

Return on assets
21.8%
PEG ratio
1.2
P/E ratio
44.1
P/B ratio
13.6
EV / EBITDA
27.7
Industry P/E
44.0
ROCE
35.4%
ROCE 5y average
27.4%
ROE
28.4%
Debt / Equity
0.1
Interest coverage
54.3
Dividend yield
1.8%
ROE 3y average
20.0%
ROE last year
28.0%

Annual P&L

Annual revenue
₹829 Cr
Annual profit
₹163 Cr
Operating margin
32.0%
Net profit margin
19.7%
EBITDA margin
31.7%
Sales growth 3y
16.3%
Sales growth 5y
10.9%
Profit growth 3y
36.0%
Profit growth 5y
8.0%
EPS
₹10.2
Sales growth TTM
21.0%
Profit growth TTM
70.0%
Dividend payout
137.0%

Quarter P&L

Sales latest quarter
₹240 Cr
Profit latest quarter
₹51 Cr
YoY quarterly sales growth
24.3%
YoY quarterly profit growth
34.2%
OPM latest quarter
32.2%

Balance Sheet

Book Value
₹36.8
Face Value
₹10.0
Total debt
₹51 Cr
Total cash
₹68 Cr
Borrowings
₹51 Cr
Reserves / Equity
2.7

Cash Flow

Operating cash flow
₹213 Cr
Free cash flow
₹198 Cr
FCF yield
2.4%
Net cash flow
₹21 Cr

Shareholding

Promoter holding
60.9%
FII holding
5.4%
DII holding
20.9%
Public holding
12.7%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Dr Lal Pathlabs1,896.9056.631,8390.74170.528.0797.719.128.0
Vijaya Diagnost.1,443.3079.314,8660.1453.137.6231.022.820.5
Metropolis Healt526.9052.510,9310.3756.925.8450.216.617.8
Thyrocare Tech.506.8544.68,0671.7951.334.1240.024.335.4
Nephrocare Health Services624.7073.86,2820.0032.034.9281.823.715.3
Krsnaa Diagnost.531.0017.41,7230.3715.8-19.1210.719.912.7
Suraksha Diagno.311.4045.31,6220.1612.938.487.720.817.3
Median311.4032.61,1060.0011.028.095.219.120.5

Competes with: 3B Blackbio Dx Limited, Dr. Lal Path Labs Ltd., Gaudium IVF and Women Health Limited, Health X Platform Limited, Krsnaa Diagnostics Limited, Metropolis Healthcare Limited, Nephrocare Health Services Limited, One Global Service Provider Limited, Pramodini Medicare Limited, Sastasundar Ventures Limited, Suraksha Diagnostic Limited, Vijaya Diagnostic Centre Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales135148135154157177166187193217196224240
Expenses100110103121115129124130135145138149163
Material Cost495560475662
Change in Inventories0.300.150.040.09-0.510.25
Purchases of Stock-in-Trade0.460.070.210.040.770.03
Employee Cost333333363640
Other Expenses474752555661
Operating Profit35383234424842575871587577
OPM %26252322272725303033303432
Other Income1333434553-155
Exceptional items (within Other Income)000-6.1600
Interest1111111111-021
Depreciation10111313111317141112221412
Profit before tax25282023343728475063356468
Tax %31282625292832542424212425
Net Profit17201517242619223848284951
EPS in Rs1.091.280.971.121.521.681.201.362.453.021.822.963.28
Diluted EPS in Rs4.167.339.031.812.983.22

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales183241304356403434495589527572687829876
Expenses110147189212249261323353403432498566594
Material Cost188219
Change in Inventories0.81-0.23
Purchases of Stock-in-Trade21.09
Employee Cost127138
Other Expenses179209
Operating Profit7394115145154174171236123140190263282
OPM %40393841384035402324283232
Other Income87-1521111122999151212
Exceptional items (within Other Income)0-6.16
Interest0100121356443
Depreciation13181820263230343947555960
Profit before tax6882821451381401522288996145213231
Tax %353748363837262327283824
Net Profit445243938588113176646991163176
EPS in Rs2.983.212.665.795.385.587.13114.064.455.761011
Diluted EPS in Rs1710
Dividend Payout %171104125581243011745148135122137

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
13%
5 years
11%
3 years
16%
TTM
21%

Compounded profit growth

10 years
12%
5 years
8%
3 years
36%
TTM
70%

Stock price CAGR

10 years
9%
5 years
6%
3 years
40%
1 year
25%

Return on equity

10 years
21%
5 years
20%
3 years
20%
Last year
28%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital5154545453535353535353159
Reserves226312354390382314374474481474494426
Borrowings000021282123422551
Other Liabilities534430363790106607475121111
Minority Interest0.300.52
Total Liabilities329410438479475469541607632644693747
Fixed Assets196259259299294269253285294306297317
CWIP61170158323143
Investments86931041209590126146144162162177
Other Assets4256586084105154173192173220250
Total Assets329410438479475469541607632644693747

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity346890107100168115113129168191213
Cash from Investing Activity-18-18-42-43-121-49-24-39-91-53-23
Cash from Financing Activity-23-45-49-64-94-165-62-89-86-85-130-170
Net Cash Flow-65-0-0-54404-8821
Free Cash Flow2553536361158939988107146198

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10118101114335859283933
Inventory Days4856656660645253621048981
Days Payable510625256856365488146109
Cash Conversion Cycle53576750461029756744-184
Working Capital Days282191028-819413171319
ROCE %2428333035364217182535

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters717171717171717171616161
FIIs3.463.352.902.491.932.772.413.234.854.965.375.43
DIIs131415151515151513212121
Public121211111211121111141313
No. of Shareholders72,00068,84464,82361,63659,37756,66657,40354,56654,14277,61973,37773,064

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +18.6% (₹421.33 → ₹499.70)Brick size ₹17.22 (fixed)Bricks 44
₹400₹600₹500Nov '25Jan '26Mar '26May '26Jul '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹499.70 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-169inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

40,62,277inr

2026-03-31

volume growth %

28.00pct

2026-06-30

News

News and filings about Thyrocare Technologies Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • diagnostic reagents & reagent-rental analyser kits
  • laboratory consumables (tubes, vials)
  • point-of-care testing devices & strips
  • radiopharmaceutical inputs (FDG/PSMA/DOPA) for PET-CT imaging

Sells to

  • Docon Technologies Private Limited · diagnostic testing services & consumables (related-party, API Holdings group)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Healthcare Service Provider
Classification
Healthcare › Healthcare Service Provider
ISIN
INE594H01019

Business segments

  • Diagnostic Testing Services · 93%
  • Imaging Services · 6%
  • Others · 0%

Plants

  • Central Processing Laboratory, Turbhe · Navi Mumbai, Maharashtra
  • Central Processing Laboratory, Udyog Vihar · Gurgaon, Haryana
  • Nueclear Healthcare cyclotron & PET-CT facilities

News impact

Big market events that reach Thyrocare Technologies Limited, and how the effect spreads.

24 Sept, 11:36 IST · Market event · high impact

Nephrocare shares tumble 5% | What’s driving the decline?

Large holders are selling about Rs 650 crore of kidney-care firm Nephrocare at a 5% discount, hurting current shareholders short-term while letting new buyers enter cheaper.

Healthcare

Who it hits first

  • Nephrocare Health Services, which runs kidney dialysis clinics, fell over 5% after reports that large holders want to sell about Rs 650 crore of shares at Rs 705 each.
  • That Rs 705 price is about 5% below the last close of Rs 741.90, so the market is repricing toward the cheaper deal price.
  • The business itself is unchanged — only the shareholding is shifting.

Who may gain

  • Buyers who get the block at Rs 705 gain an instant 5% discount to the Rs 741.90 close.
  • Patient investors who wanted Nephrocare shares can now buy the dip if the fall overdoes the discount.

Along the supply chain

Downstream

No direct downstream impact — hospitals it serves, including Max Healthcare, Fortis Healthcare, and Medanta, see no change to orders or contracts from this share sale.

Upstream

No direct supply-chain link upstream — Nephrocare lists no suppliers in the pack, and a shareholder sale does not change what it buys.

Where demand moves

Business

No change to patient visits, dialysis sessions, or clinic revenue — the Rs 650 crore sale moves existing shares between investors, not customers.

Capital

About Rs 650 crore of new share supply near Rs 705 pulls the price down short-term as traders sell; bargain hunters absorbing the block provide the offsetting buy flow.

How it spreads across sectors

Healthcare

No sector-wide impact — a single-company share sale with no change to hospital or lab demand; peers should trade flat.

When it plays out

Immediate

1–7 days: Nephrocare trades heavy near Rs 705 as the Rs 650 crore block clears; peers flat.

Medium term

1–6 months: price follows clinic results again, not the block; no lasting sector effect.

Short term

1–4 weeks: discount overhang fades if buyers hold; price stabilises unless more selling appears.

Who it hits first

  • Krsnaa Diagnostics won a 15-year Punjab government deal to run PET-CT cancer-imaging scans, opening a costly high-value scan business it did not have before.
  • The stock jumped 11% as investors priced in years of steady scan income from the long contract.

Who may gain

  • Krsnaa Diagnostics gains a 15-year revenue stream and a new high-value PET-CT line; no listed peer shares the award.

Along the supply chain

Downstream

Punjab government hospitals and patients get advanced cancer imaging locally instead of referring cases out.

Upstream

PET-CT scanners come from unlisted global makers (Siemens, GE, Philips) and tracer supply has no listed pure-play, so no listed upstream impact.

Where demand moves

Business

Punjab's public hospitals will send PET-CT scan demand to Krsnaa's new centres for 15 years; scanner makers and tracer suppliers are unlisted so no listed upstream benefit.

Capital

Money rotates into KRSNAA shares on the repricing; no sector-wide rotation since the award is exclusive to one company.

How it spreads across sectors

Healthcare

Mild positive: validates the PPP route for high-end diagnostics and hints other states may tender similar PET-CT deals.

When it plays out

Immediate

Shares already up 11%; follow-through depends on disclosed order value and rollout plan.

Medium term

Scan volumes and revenue/margin contribution from PET-CT over 1-6 months and beyond.

Short term

Agreement signing, centre commissioning schedule, and management commentary in quarterly results.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

23 Jun 2026unspecified₹7
28 Nov 2025bonus₹0
24 Oct 2025interim₹7
25 Jul 2025unspecified₹21
16 Aug 2024unspecified₹18
20 Apr 2023interim₹18
11 May 2022interim₹15
17 Jun 2021unspecified₹15

Splits, bonuses & buybacks

  • daily-prices repair: 14 rows from NSE's archive (replace 6, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
13 Aug 2026DOCON TECHNOLOGIES PRIVATE LIMITEDSELL1,31,68,657₹624.00
13 Aug 2026HSBC MUTUAL FUNDBUY29,99,731₹624.00
13 Aug 2026KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITEDBUY24,00,000₹624.00
13 Aug 2026DSP MUTUAL FUNDBUY13,21,363₹624.00
13 Aug 2026DOCON TECHNOLOGIES PRIVATE LIMITEDSELL10,00,000₹631.71
13 Aug 2026ICICI PRUDENTIAL MUTUAL FUNDBUY8,01,000₹624.00

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
18 Aug 2026Docon Technologies Private Limited · PromoterUNKNOWN7,94,69,6964,916.00
13 Aug 2026Docon Technologies Private Limited · PromoterUNKNOWN1,75,00,0001,088.68
13 Aug 2026Docon Technologies Private Limited · PromoterSELL1,31,68,657815.05
13 Aug 2026Docon Technologies Private Limited · PromoterSELL26,01,039162.81
7 Aug 2026Mohammad Shadab Alam · Designated PersonSELL1000.01

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.